X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (78642) 78642
Newspaper Article (1208) 1208
Newsletter (751) 751
Magazine Article (245) 245
Book Chapter (170) 170
Book / eBook (68) 68
Conference Proceeding (38) 38
Transcript (35) 35
Trade Publication Article (25) 25
Dissertation (24) 24
Web Resource (16) 16
Book Review (15) 15
Publication (11) 11
Reference (8) 8
Government Document (6) 6
Streaming Video (4) 4
Paper (3) 3
Journal / eJournal (2) 2
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (57916) 57916
female (30502) 30502
male (29049) 29049
interferon (22457) 22457
animals (20557) 20557
adult (20420) 20420
middle aged (20189) 20189
immunology (14882) 14882
interferon-alpha - therapeutic use (14588) 14588
mice (13553) 13553
antiviral agents - therapeutic use (13006) 13006
aged (10962) 10962
treatment outcome (10701) 10701
oncology (9544) 9544
recombinant proteins (8804) 8804
cytokines (8565) 8565
therapy (7424) 7424
hepatitis c, chronic - drug therapy (7387) 7387
health aspects (7367) 7367
gastroenterology & hepatology (7355) 7355
biological response modifiers (6994) 6994
interferon-gamma (6883) 6883
inflammation (6502) 6502
drug therapy, combination (6406) 6406
cancer (6300) 6300
hepatitis c (6136) 6136
interferon-alpha (6107) 6107
interferons - therapeutic use (6092) 6092
care and treatment (6021) 6021
expression (6011) 6011
research (5948) 5948
immunotherapy (5889) 5889
ribavirin - therapeutic use (5887) 5887
infections (5801) 5801
infection (5639) 5639
analysis (5618) 5618
pharmacology & pharmacy (5479) 5479
lymphocytes (5332) 5332
infectious diseases (5063) 5063
medicine, research & experimental (5024) 5024
hepatitis (5017) 5017
proteins (5004) 5004
adolescent (4934) 4934
research article (4828) 4828
medicine (4644) 4644
gene expression (4589) 4589
hepatitis c virus (4572) 4572
dendritic cells (4493) 4493
antineoplastic agents - therapeutic use (4492) 4492
t cells (4401) 4401
immune response (4257) 4257
lymphocytes t (4253) 4253
ribavirin (4225) 4225
hepacivirus - genetics (4224) 4224
mice, inbred c57bl (4165) 4165
cell biology (4151) 4151
multiple sclerosis (4138) 4138
immune system (4063) 4063
time factors (4043) 4043
virology (4038) 4038
multidisciplinary sciences (4030) 4030
viruses (3881) 3881
antigens (3866) 3866
hematology (3848) 3848
genotype (3791) 3791
drug therapy (3773) 3773
disease (3741) 3741
activation (3689) 3689
interferon-alpha - administration & dosage (3687) 3687
patients (3636) 3636
polyethylene glycols - therapeutic use (3616) 3616
mice, inbred balb c (3594) 3594
γ-interferon (3557) 3557
cells, cultured (3551) 3551
hepatitis c - drug therapy (3549) 3549
interferon type i - therapeutic use (3465) 3465
t-cells (3390) 3390
interferon-gamma - metabolism (3351) 3351
prognosis (3344) 3344
recombinant proteins - therapeutic use (3333) 3333
risk factors (3322) 3322
interferon-alpha - adverse effects (3319) 3319
cells (3244) 3244
apoptosis (3224) 3224
science (3188) 3188
young adult (3186) 3186
antineoplastic combined chemotherapy protocols - therapeutic use (3133) 3133
medical research (3128) 3128
liver (3115) 3115
disease models, animal (3106) 3106
interferon-beta - therapeutic use (3048) 3048
microbiology (3044) 3044
vaccines (3007) 3007
follow-up studies (2999) 2999
genetic aspects (2994) 2994
retrospective studies (2965) 2965
immunity (2964) 2964
biochemistry & molecular biology (2952) 2952
medicine & public health (2903) 2903
studies (2884) 2884
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (53) 53
Online Resources - Online (15) 15
UofT at Mississauga - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
UTL at Downsview - May be requested (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Gerstein Science - Not Returned (1) 1
Gerstein Science - Periodical Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (76964) 76964
Japanese (1195) 1195
Russian (1020) 1020
German (952) 952
French (713) 713
Chinese (591) 591
Spanish (473) 473
Polish (230) 230
Italian (211) 211
Portuguese (183) 183
Hungarian (121) 121
Czech (40) 40
Dutch (39) 39
Korean (39) 39
Swedish (36) 36
Danish (34) 34
Finnish (31) 31
Norwegian (30) 30
Croatian (27) 27
Serbian (25) 25
Ukrainian (24) 24
Hebrew (23) 23
Slovak (23) 23
Romanian (18) 18
Turkish (14) 14
Bulgarian (8) 8
Arabic (2) 2
Albanian (1) 1
Icelandic (1) 1
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
PloS one, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133236
Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy.... 
VIRUS-INFECTION | CHEMOKINES | MULTIDISCIPLINARY SCIENCES | CHRONIC HEPATITIS-C | PROTEIN-10 | GENOTYPE 1 INFECTION | PREDICTIVE-VALUE | RIBAVIRIN | INDUCTION | ASSOCIATION | SPONTANEOUS CLEARANCE | Recurrence | Interferons | Humans | Fluorenes - therapeutic use | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Male | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Virus Replication - drug effects | Chemokine CXCL10 - blood | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Dipeptidyl Peptidase 4 - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Convalescence | Chemokine CXCL10 - genetics | Protein Processing, Post-Translational | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Infection | Care and treatment | Analysis | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Therapy | Laboratories | Chronic infection | Critical care | Amino acids | Infections | Ribavirin | Clinical outcomes | Proteins | Genotype & phenotype | Hepatitis | Immunology | Hepatology | Post-translation | Pretreatment | Drug dosages | Genotypes | Statistical analysis | Liver diseases | Dendritic cells | Serum levels | Studies | Infectious diseases | CXCL10 protein | Biomarkers | Chemokines | Virus Replication/drug effects | Viral Load/drug effects | Dipeptidyl Peptidase 4/blood | Dipeptidyl Peptidase 4/genetics | Chemokine CXCL10/blood | Hepatitis C, Chronic/blood | Life Sciences | Hepatitis C, Chronic/drug therapy | Hepatitis C, Chronic/virology | Hepatitis C, Chronic/genetics | Chemokine CXCL10/genetics | Benzimidazoles/therapeutic use | Hepacivirus/physiology | Fluorenes/therapeutic use | Antiviral Agents/therapeutic use | Sofosbuvir/therapeutic use | Hepacivirus/drug effects | Ribavirin/therapeutic use
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
.... This review article is structured to discuss antiviral therapeutics on the basis of these 3 major antiviral categories, with the caveat that some drugs discussed... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HERPES-SIMPLEX-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | POSITIVE CHRONIC HEPATITIS | CHRONIC HEPATITIS-B | ALPHA-2A PLUS RIBAVIRIN | CONGO HEMORRHAGIC-FEVER | ACUTE INTERSTITIAL NEPHRITIS | RECURRENT GENITAL HERPES | HIV-INFECTED PATIENTS | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Valacyclovir | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Valganciclovir | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Telbivudine | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Symposium on Antimicrobial Therapy
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 2, pp. 175 - 187
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 01/2011, Volume 121, Issue 1, pp. 308 - 317
...) as an important negative prognostic biomarker Given that CXCL10 mediates chemoattraction of activated lymphocytes, it is counter-intuitive that this chemokine correlates with therapeutic... 
MEDICINE, RESEARCH & EXPERIMENTAL | LIVER INFLAMMATION | GAMMA-INDUCIBLE PROTEIN-10 | VIRUS-INFECTION | DIPEPTIDYL-PEPTIDASE-IV | ANTIVIRAL THERAPY | INSULIN-RESISTANCE | IMMUNE-RESPONSES | CHRONIC HEPATITIS-C | LEVELS CORRELATE | PEGINTERFERON PLUS RIBAVIRIN | Chemokine CXCL10 - blood | Prognosis | Antiviral Agents - therapeutic use | Receptors, CXCR3 - blood | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Chemokine CXCL10 - antagonists & inhibitors | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Hepatitis C, Chronic - therapy | Recombinant Proteins | Hepatitis C, Chronic - blood | Polyethylene Glycols - therapeutic use | T-Lymphocytes - virology | Treatment Failure | Hepatitis C, Chronic - immunology | Peptide Fragments - blood | Protein Array Analysis | T-Lymphocytes - immunology | Proteases | Physiological aspects | Research | Diagnosis | Hepatitis C | Drug therapy | Chemokines | Hepatitis C, Chronic/therapy | T-Lymphocytes/immunology | Polyethylene Glycols/therapeutic use | Dipeptidyl Peptidase 4/blood | Receptors, CXCR3/blood | Chemokine CXCL10/blood | T-Lymphocytes/virology | Hepatitis C, Chronic/blood | Interferon-alpha/therapeutic use | Chemokine CXCL10/antagonists & inhibitors | Life Sciences | Immunology | Antiviral Agents/therapeutic use | Hepatitis C, Chronic/immunology | Peptide Fragments/blood | Ribavirin/therapeutic use | Hepatitis C, Chronic/virology
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2017, Volume 2019, Issue 10, p. CD003280
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disease that causes progressive or relapsing and remitting weakness and... 
Immunologic Factors | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Chronic inflammatory demyelinating polyradiculopathy | Immunosuppressive Agents | Chronic inflammatory demyelinating polyradiculoneuropathy | Interferon beta‐1a | Treatment Outcome | Immunosuppressive and immunomodulatory treatment | Randomized Controlled Trials as Topic | Neurology | Interferon‐beta | Anti‐Inflammatory Agents | Azathioprine | Methotrexate | Medicine General & Introductory Medical Sciences | Immunoglobulins, Intravenous | Peripheral Neuropathy | SYSTEMIC-LUPUS-ERYTHEMATOSUS | Interferon-beta [therapeutic use] | Immunologic Factors [therapeutic use] | Humans | GUILLAIN-BARRE-SYNDROME | Immunosuppressive Agents [therapeutic use] | Anti-Inflammatory Agents [therapeutic use] | Azathioprine [therapeutic use] | RANDOMIZED CONTROLLED TRIAL | DISEASE-MODIFYING THERAPY | MEDICINE, GENERAL & INTERNAL | Interferon beta-1a | HIGH-DOSE CYCLOPHOSPHAMIDE | INTRAVENOUS IMMUNOGLOBULIN | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating [drug therapy] | TERM-FOLLOW-UP | PLACEBO-CONTROLLED TRIAL | STEM-CELL TRANSPLANTATION | Methotrexate [therapeutic use] | MYCOPHENOLATE-MOFETIL | Interferon-beta - therapeutic use | Azathioprine - therapeutic use | Interferon beta-1a - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Immunosuppressive Agents - therapeutic use | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy | Anti-Inflammatory Agents - therapeutic use | Methotrexate - therapeutic use | Immunologic Factors - therapeutic use
Journal Article
The Medical clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | NOD MICE | ANTI-CD3 MONOCLONAL-ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | MEDICINE, GENERAL & INTERNAL | ISLET GRAFT-SURVIVAL | PHASE-II TRIAL | RECENT-ONSET | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article